1049 related articles for article (PubMed ID: 8808830)
1. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Kobayashi H; Gotoh J; Hirashima Y; Fujie M; Sugino D; Terao T
J Biol Chem; 1995 Apr; 270(14):8361-6. PubMed ID: 7713945
[TBL] [Abstract][Full Text] [Related]
3. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
5. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
6. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
9. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
10. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models.
Kobayashi H; Shinohara H; Fujie M; Gotoh J; Itoh M; Takeuchi K; Terao T
Int J Cancer; 1995 Nov; 63(3):455-62. PubMed ID: 7591248
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
Kobayashi H; Shinohara H; Takeuchi K; Itoh M; Fujie M; Saitoh M; Terao T
Cancer Res; 1994 Feb; 54(3):844-9. PubMed ID: 8306348
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
Kobayashi H; Gotoh J; Kanayama N; Hirashima Y; Terao T; Sugino D
Cancer Res; 1995 May; 55(9):1847-52. PubMed ID: 7728751
[TBL] [Abstract][Full Text] [Related]
14. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
15. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
16. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
17. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
18. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
19. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]